Swedish Orphan Biovitrum publ AB: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Swedish Orphan Biovitrum AB Proposes No FY 2012 Dividend; Issues FY 2013 Financial Guidance in Line with Analysts' Estimates
Swedish Orphan Biovitrum AB announced that its Board of Directors proposes paying no dividend for fiscal year 2012. This is unchanged from fiscal year 2011. The Company also announced that it expects fiscal year 2013 total revenues in the range of between SEK 2,000 million and SEK 2,200 million. It also expects fiscal year 2013 gross margin in the range of between 57% and 59%. According to I/B/E/S estimates, analysts on average are expecting the Company to report fiscal year 2013 revenue of SEK 2,008.29 million and fiscal year 2013 gross margin of 57.29%.
Latest Developments for Swedish Orphan Biovitrum publ AB
- FDA approves Swedish Orphan Biovitrum and Biogen Idec Eloctate
- Swedish Orphan Biovitrum elects Ernst & Young as auditor
- Swedish Orphan Biovitrum and Biogen Idec announce positive efficacy and safety results from phase-3 paediatric study of investigational therapy Eloctate for haemophilia A
- Swedish Orphan Biovitrum publ AB announces FDA approval of Alprolix
- Share this
- Digg this